Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.

United European Gastroenterol J · 2021 · PMC8498403 · PMID 34077634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The use of VEDO showed a trend towards the risk of experiencing and reporting ≥1 ADR (OR 2.890; 95% CI 0.923–7.373), but this effect was less pronounced when evaluated as a multivariable predictor (OR 0.924; 95% CI 0.271–3.153).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.